Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Barinthus Biotherapeutics ( (BRNS) ) has provided an announcement.
On December 10, 2025, Barinthus Biotherapeutics announced an update on its Phase 1 AVALON clinical trial for VTP-1000, an antigen-specific immunotherapy for celiac disease. The single ascending dose portion of the trial showed that VTP-1000 was well-tolerated with no serious adverse events and demonstrated a dose-dependent pharmacological effect. The ongoing multiple ascending dose portion, which includes a gluten challenge, is expected to provide further insights in the second half of 2026. This development marks a significant step in addressing the unmet needs in celiac disease treatment, potentially positioning Barinthus Bio as a leader in immune tolerance therapies.
The most recent analyst rating on (BRNS) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Barinthus Biotherapeutics stock, see the BRNS Stock Forecast page.
Spark’s Take on BRNS Stock
According to Spark, TipRanks’ AI Analyst, BRNS is a Neutral.
Barinthus Biotherapeutics faces significant financial and technical challenges. The most impactful factors are its ongoing financial losses and bearish technical indicators. The negative valuation metrics further weigh on the stock’s attractiveness. The absence of earnings call insights and corporate events means these factors do not influence the score.
To see Spark’s full report on BRNS stock, click here.
More about Barinthus Biotherapeutics
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company specializing in developing novel immunotherapeutic candidates for autoimmune and inflammatory diseases. The company focuses on promoting immune tolerance through its proprietary SNAP-TI platform, aiming to restore immune non-responsiveness to healthy tissue. Its lead candidate, VTP-1000, targets celiac disease and is currently undergoing Phase 1 clinical trials.
Average Trading Volume: 144,903
Technical Sentiment Signal: Sell
Current Market Cap: $28.69M
See more insights into BRNS stock on TipRanks’ Stock Analysis page.